Newswise — PHILADELPHIA—Russell J. Schilder, M.D., recently joined the Kimmel Cancer Center at Jefferson as Director of the Gynecologic Medical Oncology Program, and was also named professor of Medical Oncology and Gynecology at Jefferson Medical College of Thomas Jefferson University in the Department of Medical Oncology.
Prior to his arrival at Thomas Jefferson University Hospital, Dr. Schilder served as a professor in the Department of Medical Oncology and Chief of Gynecologic Medical Oncology at Fox Chase Cancer Center.
“It’s an honor to be a part of this outstanding team of highly-skilled clinicians at Jefferson,” Dr. Schilder said. “This hospital has a great reputation, particularly with their approach to individualized patient care, the latest, cutting-edge technology and research, and a much-appreciated sense of community. I’m looking forward to my time here as the director of Gynecologic Medical Oncology.”
A graduate of Rutgers University, Dr. Schilder received both his M.S. and medical degree from the University of Miami. Dr. Schilder’s postgraduate training began at Temple University Hospital with an internship and residency in Internal Medicine. In 1989, he completed a joint hematology and oncology fellowship at Temple University Hospital and Fox Chase Cancer Center.
Board-certified in internal medicine, hematology and oncology, Dr. Schilder’s research in gynecologic oncology has been published extensively in academic journals, including the Journal of Clinical Oncology and the Clinical Cancer Research. Additionally, he serves as a reviewer for academic oncology journals, including Cancer Research.
Dr. Schilder is the principal investigator for many clinical trials that study the treatment of persistent or recurrent ovarian cancer. He is also the co-principal investigator for many other clinical trials within the Gynecologic Oncology Group.
A member of several professional societies including the American Society of Clinical Oncology, American Association of Cancer Research and the International Gynecologic Cancer Society, Dr. Schilder serves on the advisory boards of several pharmaceutical companies and has presented his oncology research at national and international scientific meetings.
His research interests include evaluating new treatments for gynecologic malignancies and conducting phase I trials for new drug development. He has written more than 150 book chapters, articles, and abstracts.
“Dr. Schilder is an incredible addition to our medical oncology team,” said William Kevin Kelly, DO, Director, Division of Solid Tumor Oncology, at Thomas Jefferson University. “The hospital and university staff and our patients will greatly benefit from his wealth of knowledge, compassion and decades of medical experience in the fields of cancer and gynecology.”
##
Thomas Jefferson University Hospitals (TJUH) are dedicated to excellence in patient care, patient safety and the quality of the healthcare experience. Consistently ranked by U.S. News & World Report among the nation's top hospitals, Thomas Jefferson University Hospital, established in 1825, has over 900 licensed acute care beds with major programs in a wide range of clinical specialties. TJUH is one of the few hospitals in the U.S. that is both a Level 1 Trauma Center and a federally-designated regional spinal cord injury center. TJUH patient care facilities include Jefferson Hospital for Neuroscience, the region’s only dedicated hospital for neuroscience, Methodist Hospital in South Philadelphia, and additional patient care facilities throughout Pennsylvania and New Jersey. TJUH partners with its education affiliate, Thomas Jefferson University.
RSS